Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

被引：16

作者：

Tomonari, Tetsu ^{[1
]}

Tani, Joji ^{[2
]}

Sato, Yasushi ^{[3
]}

Tanaka, Hironori ^{[1
]}

Tanaka, Takahiro ^{[1
]}

Taniguchi, Tatsuya ^{[1
]}

Morishita, Akihiro ^{[2
]}

Okamoto, Koichi ^{[1
]}

Sogabe, Masahiro ^{[1
]}

Miyamoto, Hiroshi ^{[1
]}

Muguruma, Naoki ^{[1
]}

Masaki, Tsutomu ^{[2
]}

Takayama, Tetsuji ^{[1
]}

机构：

[1] Tokushima Univ, Dept Gastroenterol & Oncol, Grad Sch Biomed Sci, Tokushima, Japan

[2] Kagawa Univ, Dept Gastroenterol & Neurol, Grad Sch Med, Takamatsu, Kagawa, Japan

[3] Tokushima Univ, Dept Community Med Gastroenterol & Oncol, Grad Sch Biomed Sci, 2-50-1 Kuramoto, Tokushima 770042, Japan

来源：

CANCER MEDICINE | 2023年 / 12卷 / 03期

关键词：

atezolizumab; bevacizumab; hepatocellular carcinoma; SERUM-ALBUMIN; SORAFENIB; LENVATINIB; MUSCLE;

D O I：

10.1002/cam4.5145

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim We analyzed the association between the modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u-HCC). Methods In this retrospective observational study, we included 71 u-HCC patients treated with Atezo+Bev between September 2020 and September 2021. Patients were grouped corresponding to the mALBI grade at the start of treatment (mALBI 1+2a or mALBI 2b+3) and analyzed for therapeutic effect and the transition rate to secondary treatment. Results According to the Response Evaluation Criteria in Solid Tumors, the overall response rate was significantly higher for the mALBI 1+2a group, than for the mALBI 2b+3 group, with 26.2% and 3.4%, respectively. The progression-free survival (PFS) was significantly longer in the mALBI 1+2a group (10.5 months) than in the mALBI 2b+3 group (3.0 months). In the multivariate analysis, an mALBI of 1+2a was found to be an independent factor of PFS. The rate of second-line treatment with multi-targeted agents was also significantly higher in the mALBI 1+2a group. Conclusions In real-world practice, Atezo+Bev treatment might have higher therapeutic efficacy in u-HCC patients with mALBI 1+2a.

引用

页码：2646 / 2657

页数：12

共 39 条

[1] Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade [J].

Aoki, Tomoko ;

Kudo, Masatoshi ;

Ueshima, Kazuomi ;

Morita, Masahiro ;

Chishina, Hirokazu ;

Takita, Masahiro ;

Hagiwara, Satoru ;

Ida, Hiroshi ;

Minami, Yasunori ;

Tsurusaki, Masakatsu ;

Nishida, Naoshi .

CANCERS, 2020, 12 (10) :1-13

[2] Serum albumin is associated with skeletal muscle in elderly men and women [J].

Baumgartner, RN ;

Koehler, KM ;

Romero, L ;

Garry, PJ .

AMERICAN JOURNAL OF CLINICAL NUTRITION, 1996, 64 (04) :552-558

[3] Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial [J].

Bruix, Jordi ;

Qin, Shukui ;

Merle, Philippe ;

Granito, Alessandro ;

Huang, Yi-Hsiang ;

Bodoky, Gyrogy ;

Pracht, Marc ;

Yokosuka, Osamu ;

Rosmorduc, Olivier ;

Breder, Valeriy ;

Gerolami, Rene ;

Masi, Gianluca ;

Ross, Paul J. ;

Song, Tianqiang ;

Bronowicki, Jean-Pierre ;

Ollivier-Hourmand, Isabelle ;

Kudo, Masatoshi ;

Cheng, Ann-Lii ;

Llovet, Josep M. ;

Finn, Richard S. ;

LeBerre, Marie-Aude ;

Baumhauer, Annette ;

Meinhardt, Gerold ;

Han, Guohong .

LANCET, 2017, 389 (10064) :56-66

[4] Serum albumin: Relationship to inflammation and nutrition [J].

Don, BR ;

Kaysen, G .

SEMINARS IN DIALYSIS, 2004, 17 (06) :432-437

[5]

European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]

[6] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[7] Association between nutritional blood-based biomarkers and clinical outcome in sarcopenia patients [J].

Gariballa, Salah ;

Alessa, Awad .

CLINICAL NUTRITION ESPEN, 2018, 25 :145-148

[8] The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study [J].

Hatanaka, Takeshi ;

Naganuma, Atsushi ;

Shibasaki, Mitsuhiko ;

Kohga, Tatsuya ;

Arai, Yosuke ;

Nagashima, Tamon ;

Ueno, Takashi ;

Namikawa, Masashi ;

Saito, Shuichi ;

Hoshino, Takashi ;

Takizawa, Daichi ;

Arai, Hirotaka ;

Makita, Fujio ;

Kakizaki, Satoru ;

Harimoto, Norifumi ;

Shirabe, Ken ;

Uraoka, Toshio .

ONCOLOGY, 2021, 99 (04) :203-214

[9] Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice [J].

Hayakawa, Yuka ;

Tsuchiya, Kaoru ;

Kurosaki, Masayuki ;

Yasui, Yutaka ;

Kaneko, Shun ;

Tanaka, Yuki ;

Ishido, Shun ;

Inada, Kento ;

Kirino, Sakura ;

Yamashita, Koji ;

Nobusawa, Tsubasa ;

Matsumoto, Hiroaki ;

Kakegawa, Tatsuya ;

Higuchi, Mayu ;

Takaura, Kenta ;

Tanaka, Shohei ;

Maeyashiki, Chiaki ;

Tamaki, Nobuharu ;

Nakanishi, Hiroyuki ;

Itakura, Jun ;

Takahashi, Yuka ;

Asahina, Yasuhiro ;

Okamoto, Ryuichi ;

Izumi, Namiki .

INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) :392-402

[10] Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience [J].

Hiraoka, Atsushi ;

Kumada, Takashi ;

Tada, Toshifumi ;

Hirooka, Masashi ;

Kariyama, Kazuya ;

Tani, Joji ;

Atsukawa, Masanori ;

Takaguchi, Koichi ;

Itobayashi, Ei ;

Fukunishi, Shinya ;

Tsuji, Kunihiko ;

Ishikawa, Toru ;

Tajiri, Kazuto ;

Ochi, Hironori ;

Yasuda, Satoshi ;

Toyoda, Hidenori ;

Ogawa, Chikara ;

Nishimura, Takashi ;

Hatanaka, Takeshi ;

Ohama, Hideko ;

Nouso, Kazuhiro ;

Morishita, Asahiro ;

Tsutsui, Akemi ;

Nagano, Takuya ;

Itokawa, Norio ;

Okubo, Tomomi ;

Arai, Taeang ;

Imai, Michitaka ;

Koizumi, Yohei ;

Nakamura, Shinichiro ;

Joko, Kouji ;

Iijima, Hiroko ;

Hiasa, Yoichi ;

Kudo, Masatoshi .

CANCER REPORTS, 2022, 5 (02)

← 1 2 3 4 →